Clinical Data's Total Lab Care Group in Service Agreement with Greater Cincinnati Associated Physicians, Inc.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA) announced today that the Total Lab Care (TLC(sm)) Group of its Vital Diagnostics division has signed a Laboratory Service Agreement (LSA) with Greater Cincinnati Associated Physicians, Inc., Cincinnati, Ohio (GCAP). This multi-year, comprehensive service agreement provides consultative services for the operation of GCAP's new state of the art clinical laboratory. It is anticipated that the new laboratory will perform over 500,000 tests annually.

Gus Gardner, President, Clinical Data Sales and Services, said, "GCAP is the largest independent medical group in Cincinnati and a great business partner for Clinical Data. Their commitment to quality in delivering healthcare allows our TLC Group to showcase our competencies in regulatory compliance, laboratory logistics, billing, reimbursement and operations. GCAP has been recognized by the National Committee for Quality Assurance (NCQA) as a medical practice that makes systematic use of clinical information to deliver excellent patient care, and we are pleased to be chosen as their lab management provider."

Pamela Zipperer-Davis, CEO of GCAP, commented, "By partnering with a laboratory expert like Clinical Data to establish a lab internal to our group operations and processes, GCAP will be able to continue to improve our quality and patient service, our two most important objectives. Our patients will have blood drawn in their doctor's office, and the lab will be able to return many lab results on the same day to the physician which allows same day patient notification. GCAP will be better able to manage chronic diseases with high quality and timely lab results. We are excited about our new partnership."

About Greater Cincinnati Associated Physicians (GCAP)

Greater Cincinnati Associated Physicians (GCAP) was formed in May 1994 through the consolidation of 18 independent primary care physicians with practices located throughout Western Hamilton County. This core group of physicians saw the need to develop a large, fully integrated primary care group practice in order to remain competitive in the rapidly changing healthcare market. By joining forces, these physicians are now able to provide more effective and efficient patient care through shared processes for patient care, group purchasing, a common information system, and managed care contracting. Over the past several years, GCAP has experienced considerable growth with a current physician membership of 31 physicians; 13 specializing in Internal Medicine, and 19 specializing in Family Medicine. An increase in GCAP's scope of services has allowed the group to better manage the delivery of patient care. The addition of GCAP ancillary services which include Physical Therapy, Radiology, Imaging and Laboratory services has proven to be a much valued convenience to our patients. As GCAP looks ahead, one thing is certain - patient satisfaction will continue to be our #1 priority and the group will remain committed to providing superior medical care at cost competitive rates in a managed care environment.

About Clinical Data, Inc.

Clinical Data, Inc., a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth[TM]; Cogenics[TM]; and Vital Diagnostics[TM]. The Pharmacogenomics and Molecular Services[TM] division, Cogenics, consolidates operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc., Icoria, Inc., and Genome Express SA to provide a comprehensive range of molecular biology and pharmacogenomics services to pharmaceutical, biotech, academic, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. PGxHealth builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals, Icoria, and Genome Express in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth develops, validates and commercializes novel Therapeutic Diagnostics[TM], in some instances in combination with new and existing therapeutics, to improve patient care. In addition, PGxHealth has a therapeutic drug candidate, vilazodone, currently in late stage clinical trials for the treatment of depression. Vital Diagnostics serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide. With a focus on the physician's office, hospital and small-to-medium sized laboratory segments and customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data is headquartered in Newton, Mass. with operations in Texas, Connecticut, North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005, 2006, and 2007 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com